{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T18:26:52Z","timestamp":1762021612369,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.pcad.2020.03.018","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T01:57:19Z","timestamp":1585879039000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"63","author":[{"given":"Aakash","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Rout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davit","family":"Sargsyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traymon","family":"Beavers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Kostis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2020.03.018_bb0005","doi-asserted-by":"crossref","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2016; 68: 1082\u20131115.","DOI":"10.1016\/j.jacc.2016.03.513"},{"key":"10.1016\/j.pcad.2020.03.018_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.03.018_bb0015","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcin.2016.04.009","article-title":"Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS registry","volume":"9","author":"Baber","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2020.03.018_bb0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.pcad.2018.01.003","article-title":"Selection of P2Y12 inhibitor in percutaneous coronary intervention and\/or acute coronary syndrome","volume":"60","author":"Tantry","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2020.03.018_bb0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience\/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0035","doi-asserted-by":"crossref","unstructured":"Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusm\u00e3o M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013; 310: 2510\u20132522.","DOI":"10.1001\/jama.2013.282183"},{"key":"10.1016\/j.pcad.2020.03.018_bb0040","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.03.018_bb0045","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY) investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2020.03.018_bb0055","first-page":"31","article-title":"Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systemic review and meta-analysis of randomized controlled trials with longer follow up","volume":"90","author":"Sharma","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2020.03.018_bb0060","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. [published correction appears in BMJ. 2016 Oct 17; 355: i 5600]","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2020.03.018_bb0065","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.pcad.2017.12.003","article-title":"Duration of dual antiplatelet therapy following drug-eluting stent implantation in diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Sharma","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2020.03.018_bb0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.03.018_bb0075","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor Monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. [published correction appears in JAMA. 2019 Aug 28;:]","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.03.018_bb0080","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by Clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.03.018_bb0085","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.03.018_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.pcad.2020.03.018_bb0095","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0105","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0115","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.2015.15454","article-title":"Effect of intravascular ultrasound-guided vs angiography-guided Everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"314","author":"Hong","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.03.018_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer Sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2020.03.018_bb0125","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.03.018_bb0130","doi-asserted-by":"crossref","first-page":"k 3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2020.03.018_bb0135","first-page":"1923","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy","volume":"13","author":"Lee","year":"2018","journal-title":"Euro Intervention"},{"key":"10.1016\/j.pcad.2020.03.018_bb0140","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Collaborators. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2020.03.018_bb0145","first-page":"365","article-title":"Vicaut E; OPTImal DUAL antiplatelet therapy trial investigators. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.03.018_bb0150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0155","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.03.018_bb0160","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.03.018_bb0165","first-page":"e574","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.018_bb0175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pcad.2017.12.004","article-title":"Evolution of coronary stent techonology and implications for duration of dual antiplatelet therapy","volume":"60","author":"Moon","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2020.03.018_bb0180","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation. A systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0185","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"PEGASUS-TIMI 54 steering committee and investigators. Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.03.018_bb0190","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0195","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.018_bb0200","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007541","article-title":"Risk-benefit profile of longer-than-1-year dual-antiplatelet therapy duration after drug-eluting stent implantation in relation to clinical presentation","volume":"12","author":"Palmerini","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2020.03.018_bb0205","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pcad.2018.01.004","article-title":"Anticoagulation in acute coronary syndrome-state of the art","volume":"60","author":"Zeitouni","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2020.03.018_bb0210","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.pcad.2018.01.006","article-title":"Duration of dual antiplatelet therapy for the stented patient: an update for the clinician","volume":"60","author":"Vidula","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.018_bb0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1538-7836.2009.03714.x","article-title":"Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy","volume":"8","author":"Armstrong","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.018_bb0220","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020300724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020300724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:57Z","timestamp":1758500217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062020300724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0033062020300724"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2020.03.018","relation":{},"ISSN":["0033-0620"],"issn-type":[{"type":"print","value":"0033-0620"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2020.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}